Other languages Zevra Therapeutics, Inc.

Equities

ZVRA

US4884452065

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-28 pm EDT			5-day change	1st Jan Change
4.56 ^USD	-2.15%		-2.77%	-30.38%

May. 13	Transcript : Zevra Therapeutics, Inc. - Shareholder/Analyst Call
May. 08	Earnings Flash (ZVRA) ZEVRA THERAPEUTICS Reports Q1 Revenue $3.4M	MT

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Zevra Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28
Zevra Therapeutics Says Phase 2 Trial of Idiopathic Hypersomnia Treatment Fulfilled Objectives	Mar. 27
Zevra Therapeutics, Inc. Announces Top-Line Data from the Phase 2 Clinical Trial of Kp1077 for Idiopathic Hypersomnia	Mar. 26
Sector Update: Health Care Stocks Softer in Afternoon Trading	Mar. 04
Zevra Therapeutics Says FDA Extended Arimoclomol New Drug Application Review Period	Mar. 04
Zevra Therapeutics, Inc. Appoints Alvin Shih to the Board of Directors	Jan. 23
XOMA Names Owen Hughes CEO, Jack Wyszomierski Chairman; to Make $1 Million Milestone Payment	Jan. 12
Zevra Therapeutics, Inc. Receives FDA Acceptance of Resubmission of NDA for Arimoclomol as a Treatment for Niemann-Pick Disease Type C	Jan. 08
Zevra Therapeutics Names Adrian Quartel Chief Medical Officer	Jan. 04
Zevra Therapeutics Appoints Adrian Quartel as Chief Medical Officer	Jan. 04
Zevra Therapeutics, Inc. Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration	Dec. 27
Zevra Therapeutics Resubmits Arimoclomol New Drug Application to FDA	Dec. 27
Zevra Therapeutics Completes Acer Acquisition	Nov. 20
Zevra Therapeutics, Inc. completed the acquisition of Acer Therapeutics Inc. from funds affiliated with TVM Capital Life Science and others.	Nov. 16
Zevra Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07
Zevra Therapeutics, Inc. Announces Executive Changes	23-10-10
Zevra Therapeutics, Inc. Announces Chief Executive Officer Changes	23-10-10
Zevra Therapeutics Names Neil McFarlane Chief Executive	23-10-10
Zevra Therapeutics Says Interim Data Show KP1077 for Idiopathic Hypersomnia Well-Tolerated at All Dose Levels	23-10-02
Zevra Therapeutics, Inc. Presents Full Data Set on the Cardiovascular Safety and Pharmacokinetics of Sdx, the Sole Active Pharmaceutical Ingredient in Kp1077, in Healthy Volunteers At Psych Congress 2023	23-09-09

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Zevra Therapeutics, Inc.

Equities

ZVRA

US4884452065

Other languages

Filters